Proton pump inhibitors and infection risk

被引:0
作者
Palencia-Herrejon, Eduardo [1 ]
Sanchez Artola, Beatriz [2 ]
Escobar Rodriguez, Ismael [3 ]
Gomez-Lus Centelles, Maria Luisa [4 ]
机构
[1] Hosp Infanta Leonor Madrid, Jefe Serv Med Intens, Madrid 28031, Spain
[2] Hosp Infanta Leonor, Serv Med Interna, Madrid 28031, Spain
[3] Hosp Infanta Leonor, Serv Farm, Madrid 28031, Spain
[4] Univ Complutense Madrid, Catedra Microbiol Med, E-28040 Madrid, Spain
关键词
Proton pump inhibitors; Gastrointestinal infections; Respiratory infections; CLOSTRIDIUM-DIFFICILE INFECTION; COMMUNITY-ACQUIRED PNEUMONIA; STRESS-ULCER PROPHYLAXIS; CRITICALLY-ILL PATIENTS; SPONTANEOUS BACTERIAL PERITONITIS; RANDOMIZED CONTROLLED-TRIALS; ACID-SUPPRESSIVE DRUGS; GASTRIC-ACID; NOSOCOMIAL PNEUMONIA; MECHANICAL VENTILATION;
D O I
暂无
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Gastric antisecretory drugs, especially proton pump inhibitors, are among the most used drugs both in ambulatory and hospital settings, and prescription does not always follows approved indications. Experimental data suggest that gastric acid inhibition and the effects of proton pump inhibitors on the immune system can promote the development of infections. In recent years a number of observational studies have found an independent association between the use of proton pump inhibitors and an increased risk of gastrointestinal infections, including those caused by Clostridium difficile, and community and nosocomial pneumonia. This review discusses the current evidence, raises the potential pathogenic mechanisms involved and makes recommendations for current clinical practice and future research.
引用
收藏
页码:4 / 12
页数:9
相关论文
共 78 条
[1]   Omeprazole inhibits natural killer cell functions [J].
Alkim, Huseyin ;
Unal, Selahattin ;
Okur, Hamza ;
Imir, Turgut .
DIGESTIVE DISEASES AND SCIENCES, 2008, 53 (02) :347-351
[2]  
Ameijeiras AH, 2007, GAC SANIT, V21, P412
[3]  
[Anonymous], 2009, INF TER SIST NAC SAL, V33, P93
[4]  
[Anonymous], 1990, FDA Drug Review -Postapproval Risks 1976-1985
[5]   GASTRIC COLONIZATION AND PNEUMONIA IN INTUBATED CRITICALLY ILL PATIENTS RECEIVING STRESS-ULCER PROPHYLAXIS - A RANDOMIZED, CONTROLLED TRIAL [J].
APTE, NM ;
KARNAD, DR ;
MEDHEKAR, TP ;
TILVE, GH ;
MORYE, S ;
BHAVE, GG .
CRITICAL CARE MEDICINE, 1992, 20 (05) :590-593
[6]   THE EFFECT OF OMEPRAZOLE ON HUMAN NATURAL-KILLER-CELL ACTIVITY [J].
AYBAY, C ;
IMIR, T ;
OKUR, H .
GENERAL PHARMACOLOGY-THE VASCULAR SYSTEM, 1995, 26 (06) :1413-1418
[7]   Association of Proton Pump Inhibitor Therapy With Spontaneous Bacterial Peritonitis in Cirrhotic Patients With Ascites [J].
Bajaj, Jasmohan S. ;
Zadvornova, Yelena ;
Heuman, Douglas M. ;
Hafeezullah, Muhammad ;
Hoffmann, Raymond G. ;
Sanyal, Arun J. ;
Saeian, Kia .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 (05) :1130-1134
[8]   Risk of Clostridium difficile-associated disease among patients receiving proton-pump inhibitors in a Quebec medical intensive care unit [J].
Beaulieu, Mathieu ;
Williamson, David ;
Pichette, Gilbert ;
Lachaine, Jean .
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2007, 28 (11) :1305-1307
[9]   ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents [J].
Bhatt, Deepak L. ;
Scheiman, James ;
Abraham, Neena S. ;
Antman, Elliott M. ;
Chan, Francis K. L. ;
Furberg, Curt D. ;
Johnson, David A. ;
Mahaffey, Kenneth W. ;
Quigley, Eamonn M. .
CIRCULATION, 2008, 118 (18) :1894-1909
[10]   Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis [J].
Cadle, Richard M. ;
Mansouri, Mohammad D. ;
Logan, Nancy ;
Kudva, Denise R. ;
Musher, Daniel A. .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2007, 64 (22) :2359-2363